[Research Progress of Antitumor Pharmacovigilance]

Area of Science:

• Pharmacovigilance
• Oncology Drug Safety
• Regulatory Science

Background:

• China's pharmacovigilance system is in its early stages, with recent establishment of laws and standards.
• The country faces a high burden of cancer diagnoses and an increasing number of novel antitumor drug approvals.
• Existing pharmacovigilance requires enhancement in institutional frameworks, monitoring, and database infrastructure.

Purpose of the Study:

• To summarize the principles and practices of pharmacovigilance.
• To highlight the specific challenges and characteristics of antitumor pharmacovigilance in China.
• To provide a reference for the future development of antitumor pharmacovigilance in China.

Main Methods:

• Literature review of pharmacovigilance origins, objectives, procedures, and methods.
• Analysis of the current state and difficulties of antitumor pharmacovigilance in China.
• Synthesis of information to inform future development.

Main Results:

• Pharmacovigilance in China is nascent, requiring significant improvements.
• The rapid development of oncology drugs necessitates a robust antitumor pharmacovigilance framework.
• Key areas for development include institutional structures, monitoring mechanisms, and database construction.

Conclusions:

• Antitumor pharmacovigilance is essential in China due to the high cancer incidence and accelerated drug development.
• Strengthening China's pharmacovigilance system, particularly for oncology, is imperative.
• Further development should focus on improving institutional support, monitoring capabilities, and data management.